Disitamab Vedotin Phase 3 Trial Hits PFS & OS Endpoints
RemeGen Co., Ltd. announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希®), the first domestically approved antibody-drug...
Tag : clinicians
Turn Therapeutics Achieves 24-Hour Live Vaccine Stability
Turn Therapeutics has successfully maintained a live vaccine’s viability for 24 hours at room temperature using its oil suspension technology. This breakthrough — which entailed...